Real-world experience of bimekizumab for plaque psoriasis in adult patients with prior exposure to interleukin-23 inhibitors: A multicenter retrospective review

In routine clinical practice, biologic switching is common in adult patients with plaque psoriasis. While our group previously reported overall real-world 16-week and 52-week treatment outcomes of bimekizumab, a novel interleukin (IL)-17A/IL-17F inhibitor, limited information exists on switching class from an IL-23 inhibitor (IL-23i) to bimekizumab. This subset analysis of our retrospective cohort study specifically analyzes bimekizumab use following IL-23i exposure.